Fate Therapeutics (FATE) Shares Outstanding (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Shares Outstanding (Entity) data on file, last reported at $116.3 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 1.46% year-over-year to $116.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.3 million (up 1.46% YoY) and the FY2025 annual result came in at $115.4 million, up 1.26% from the prior year.
• Shares Outstanding (Entity) advanced to $116.3 million in Q1 2026, from $115.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $116.3 million in Q1 2026 to a low of $96.5 million in Q1 2022.
• A 5-year average of $106.7 million and a median of $113.8 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) increased 15.9% — and 2025, when it climbed 0.71%.
• Tracing FATE's Shares Outstanding (Entity) over 5 years: stood at $97.3 million in 2022, then grew by 1.37% to $98.6 million in 2023, then increased by 15.51% to $113.9 million in 2024, then increased by 1.26% to $115.4 million in 2025, then gained by 0.79% to $116.3 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $116.3 million (Q1 2026), $115.4 million (Q4 2025), and $115.3 million (Q3 2025), per Business Quant data.